Effects of Therapeutic Doses of Acetaminophen in Moderate Drinkers

NCT ID: NCT00400621

Last Updated: 2024-07-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2003-04-30
• Study Completion Date: 2003-09-30

Brief Summary

The study objective was to evaluate the safety of ten consecutive days of therapeutic acetaminophen dosing in moderate alcohol consumers. The main outcome was liver injury (measured by an increase in mean serum ALT or AST levels). Patients were randomly assigned to 10 days of acetaminophen or placebo. Blood tests were measured at baseline, day 4 and day 11 to look for injury. We hypothesized that there would be no difference in liver enzymes between the two groups.

Conditions

Moderate Alcohol Consumption (1-3 Drinks Per Day)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Blinding Strategy: DOUBLE

Interventions

acetaminophen

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Average baseline ethanol consumption of at least one alcoholic beverage per day before enrollment for the past two months. The estimate of ethanol intake was based on the average intake over seven days. For example, a person who ingested no alcohol on Sunday, Monday, Tuesday or Wednesday, two drinks on Thursday and four drinks on Friday and Saturday would be calculated as 10 drinks/7days = 1.4 drinks/day. The average alcoholic beverage contains 15 grams of alcohol(9).

2. Average baseline ethanol consumption of no more than three alcoholic beverages (> 45 grams of alcohol) per day, calculated as a weekly average over the preceding two months.

3. At least one alcohol-containing drink within the last 48 hours

Exclusion Criteria

Subjects were excluded from the study at baseline if any of the following were evident at baseline:

1. Serum acetaminophen level greater than 20 mcg/ml

2. Serum AST or ALT levels greater than 50 IU/L

3. If female, positive for b-HCG

4. Clinically intoxicated, psychiatrically impaired or unable to give informed consent

5. Known hypersensitivity to acetaminophen

6. History of ingesting more than four grams of acetaminophen per day for any of the four days preceding study enrollment

7. Alcoholic patients as defined by those who consume on average more than three alcoholic beverages daily

8. Currently enrolled in another trial or had been enrolled in another trial in the preceding three months

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

INDUSTRY

Sponsor Role: collaborator

Denver Health and Hospital Authority

OTHER

Sponsor Role: lead

Principal Investigators

Kennon Heard, MD

Role: PRINCIPAL_INVESTIGATOR

Rocky Mountain Poison Center

Other Identifiers

COMIRB 02-999

Identifier Type: -

Identifier Source: org_study_id